French lean on doctors over Crestor/Zetia, generic prescribing
This article was originally published in Scrip
Cost considerations have led the French authorities to clamp down on the reimbursement of two expensive cholesterol-lowering drugs, AstraZeneca's Crestor (rosuvastatin) and Merck's Zetia (ezetimibe). Also looming on the horizon, if recommendations from the Court of Auditors make any headway, are incentives for doctors to prescribe more generic medicines, particularly in the statin class.
You may also be interested in...
A legislative provision under which future COVID-19 vaccines can be made available in the UK before they are approved is also being used to offer an unlicensed flu vaccine that officials say has undergone full safety, efficacy and quality tests.
With product shortages made worse by the pandemic, companies in the UK are being asked to use a new system for notifying potential supply disruptions and any plans to discontinue specific medicines.
Two new projects have begun, one on standardizing the assessment of immune responses in individuals vaccinated in clinical trials, the other to improve understanding of potential immunity in patients who have been infected with SARS-CoV-2.